# Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH

> **NCT06350032** · PHASE3 · RECRUITING · sponsor: **AOP Orphan Pharmaceuticals AG** · enrollment: 20 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** preservative-free parenteral treprostinil

## Key facts

- **NCT ID:** NCT06350032
- **Lead sponsor:** AOP Orphan Pharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2028-11
- **Final completion:** 2028-11
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06350032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06350032, "Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06350032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*